Cargando…

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol

OBJECTIVE: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganapathy, Vaidyanathan, Stensland, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490469/
https://www.ncbi.nlm.nih.gov/pubmed/28694692
http://dx.doi.org/10.2147/COPD.S134145
_version_ 1783246990278131712
author Ganapathy, Vaidyanathan
Stensland, Michael D
author_facet Ganapathy, Vaidyanathan
Stensland, Michael D
author_sort Ganapathy, Vaidyanathan
collection PubMed
description OBJECTIVE: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmission rates, and doses of rescue medication administered in hospitalized patients with COPD who were treated with nebulized arformoterol or nebulized formoterol. METHODS: This retrospective analysis utilized data from Premier, Inc. (Charlotte, NC, USA), the largest nationwide hospital-based administrative database. COPD patients ≥40 years of age were included if they were hospitalized between January 2011 and July 2014, had no asthma diagnoses, and were treated with nebulized arformoterol or nebulized formoterol. LOS was measured from the day the patients initiated the study medication (index day). Rescue medications were defined as short-acting bronchodilators used from the index day onward. Multivariate statistical models included a random effect for hospital and controlled for patient demographics, hospital characteristics, admission characteristics, prior hospitalizations, comorbidities, pre-index service use, and pre-index medication use. RESULTS: A total of 7,876 patients received arformoterol, and 3,612 patients received nebulized formoterol. There was no significant difference in 30-day all-cause (arformoterol =11.9%, formoterol =12.1%, odds ratio [OR] =0.981, P=0.82) or COPD-related hospital readmission rates (arformoterol =8.0%, formoterol =8.0%, OR =1.002, P=0.98) after adjusting for covariates. The adjusted mean LOS was significantly shorter for arformoterol-treated vs formoterol-treated patients (4.6 vs 4.9 days, P=0.039), and arformoterol-treated patients used significantly fewer doses of rescue medications vs formoterol-treated patients (5.9 vs 6.6 doses, P=0.006). CONCLUSION: During inpatient stays, treating with arformoterol instead of nebulized formoterol may lead to shorter LOS and lower rescue medication use.
format Online
Article
Text
id pubmed-5490469
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54904692017-07-10 Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol Ganapathy, Vaidyanathan Stensland, Michael D Int J Chron Obstruct Pulmon Dis Original Research OBJECTIVE: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmission rates, and doses of rescue medication administered in hospitalized patients with COPD who were treated with nebulized arformoterol or nebulized formoterol. METHODS: This retrospective analysis utilized data from Premier, Inc. (Charlotte, NC, USA), the largest nationwide hospital-based administrative database. COPD patients ≥40 years of age were included if they were hospitalized between January 2011 and July 2014, had no asthma diagnoses, and were treated with nebulized arformoterol or nebulized formoterol. LOS was measured from the day the patients initiated the study medication (index day). Rescue medications were defined as short-acting bronchodilators used from the index day onward. Multivariate statistical models included a random effect for hospital and controlled for patient demographics, hospital characteristics, admission characteristics, prior hospitalizations, comorbidities, pre-index service use, and pre-index medication use. RESULTS: A total of 7,876 patients received arformoterol, and 3,612 patients received nebulized formoterol. There was no significant difference in 30-day all-cause (arformoterol =11.9%, formoterol =12.1%, odds ratio [OR] =0.981, P=0.82) or COPD-related hospital readmission rates (arformoterol =8.0%, formoterol =8.0%, OR =1.002, P=0.98) after adjusting for covariates. The adjusted mean LOS was significantly shorter for arformoterol-treated vs formoterol-treated patients (4.6 vs 4.9 days, P=0.039), and arformoterol-treated patients used significantly fewer doses of rescue medications vs formoterol-treated patients (5.9 vs 6.6 doses, P=0.006). CONCLUSION: During inpatient stays, treating with arformoterol instead of nebulized formoterol may lead to shorter LOS and lower rescue medication use. Dove Medical Press 2017-06-20 /pmc/articles/PMC5490469/ /pubmed/28694692 http://dx.doi.org/10.2147/COPD.S134145 Text en © 2017 Ganapathy and Stensland. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ganapathy, Vaidyanathan
Stensland, Michael D
Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title_full Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title_fullStr Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title_full_unstemmed Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title_short Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
title_sort health resource utilization for inpatients with copd treated with nebulized arformoterol or nebulized formoterol
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490469/
https://www.ncbi.nlm.nih.gov/pubmed/28694692
http://dx.doi.org/10.2147/COPD.S134145
work_keys_str_mv AT ganapathyvaidyanathan healthresourceutilizationforinpatientswithcopdtreatedwithnebulizedarformoterolornebulizedformoterol
AT stenslandmichaeld healthresourceutilizationforinpatientswithcopdtreatedwithnebulizedarformoterolornebulizedformoterol